Omniab, INC 8-K filings

OmniAb Inc. announced robust second quarter 2026 financial results, showcasing a substantial increase in revenue and an improved full-year financial outlook driven by strong business momentum and partner program progress.

OmniAb, Inc. announces the appointment of Amechi Nwachuku as Chief Operating Officer, effective July 13, 2026, with a compensation package including salary, bonus, and stock options.

OmniAb, Inc. held its 2026 Annual Meeting of Shareholders on June 17, 2026, where shareholders elected two Class I directors and ratified the appointment of Ernst & Young LLP as the independent auditor.

OmniAb Inc. announced strong first-quarter 2026 financial results, driven by milestone revenue, and raised its full-year revenue and cash guidance.

OmniAb, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2025, reporting decreased revenue but an expanded partner base and new technology launch.

OmniAb, Inc. has adopted amended and restated bylaws, enhancing corporate governance by aligning with universal proxy rules and increasing disclosure requirements for shareholder proposals.

OmniAb reports Q3 2025 revenue decline and increased net loss, while advancing strategic initiatives and strengthening its balance sheet.

OmniAb, Inc. announced a private placement raising approximately $30 million through the sale of 21.25 million common shares to new and existing investors, including officers and directors.

OmniAb, Inc. reported a significant revenue decline in Q2 2025, with net loss increasing, despite strong partner additions and new technology launches.

OmniAb, Inc. announced the final voting results from its 2025 Annual Meeting of Shareholders, confirming the election of two Class III directors and the ratification of Ernst & Young LLP as its independent registered public accounting firm.

OmniAb announces its Q1 2025 financial results, highlighting revenue growth, reduced operating expenses, and the launch of a new partner program.

OmniAb, Inc. announces the appointment of Steven C. Crouse and Philip J. Gotwals to its Board of Directors, while Sarah Boyce resigns, effective April 18, 2025.

OmniAb reported its Q4 and full year 2024 financial results, highlighting revenue increases in Q4 but a decrease for the full year, and introduced its 2025 financial guidance.

OmniAb announced its third quarter 2024 financial results, showing a decrease in revenue compared to the same period last year, but highlighted progress in its partner programs and technology platform.

OmniAb announced its second quarter 2024 financial results, reporting revenue of $7.6 million and a net loss of $13.6 million, while highlighting new partnerships and clinical progress.

OmniAb Inc. reports the resignation of Joshua Tamaroff from the Board and Audit Committee, effective June 28, 2024, and the subsequent appointment of Sarah Boyce to the Audit Committee.

OmniAb, Inc. held its 2024 Annual Meeting of Shareholders on June 18, 2024, and has announced the results of the voting on key proposals.

OmniAb's first quarter 2024 revenue decreased significantly year-over-year, primarily due to a large milestone payment in the prior year, but the company added new partnerships and saw progress in its partnered programs.

OmniAb reported its fourth quarter and full year 2023 financial results, noting a decrease in revenue due to a prior year milestone payment, but highlighted significant progress in partner programs and technology launches.